Vor Ort
Merkzettel Warenkorb
  • Produktbild: Ageing and Dementia
  • Produktbild: Ageing and Dementia
Band 53 - 12%

Ageing and Dementia

Aus der Reihe Journal of Neural Transmission. Supplementa
12% sparen

192,99 € UVP 219,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

13.07.1998

Herausgeber

Kurt Jellinger + weitere

Verlag

Springer Wien

Seitenzahl

407

Maße (L/B/H)

29,7/21/2,2 cm

Gewicht

1116 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-3-211-83114-4

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

13.07.1998

Herausgeber

Verlag

Springer Wien

Seitenzahl

407

Maße (L/B/H)

29,7/21/2,2 cm

Gewicht

1116 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-3-211-83114-4

Herstelleradresse

Springer Wien
Prinz-Eugen-Str. 8-10
1040 Wien
AT
buchhandel-buch@springer.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Ageing and Dementia
  • Produktbild: Ageing and Dementia
  • Anti-oxidants and cognitive function: a review of clinical and epidemiologic studies.- Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study).- Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam study.- The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates.- Cognitive correlates of cerebral white matter changes.- Concepts on the prognostic significance of white matter changes.- Difficulties in the clinical diagnosis of vascular dementia and dementia of the Alzheimer type — comparison of clinical classifications.- Problems of differential diagnosis between depressive pseudo- dementia and Alzheimer’s disease.- The neuropathological diagnosis of Alzheimer disease.- The progression of the lesions in Alzheimer disease: insights from a prospective clinico- pathological study.- Evolution of neuronal changes in the course of Alzheimer’s disease.- The cytoskeleton in Alzheimer disease.- Mechanisms of synaptic pathology in Alzheimer’s disease.- Proteolytic processing of Alzheimer’s disease associated proteins.- Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.- Presenilins and Alzheimer’s disease: the role of A?42.- Biological markers for the diagnosis of Alz- heimer’s disease.- Apolipoprotein E4, cholinergic integrity and the pharmaco- genetics of Alzheimer’s disease.- Cerebrospinal fluid levels of A?42 and tau: potential markers of Alzheimer’s disease.- Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing.- Positron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia.- Current diagnostic methods and outcome variables for clinical investigation of Alzheimer’s disease.- Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs.- The role of glutamate in dementia.- Neurotrophic activities and therapeutic experience with a brain-derived peptide preparation.- Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats.- The influence of Cerebrolysin® and E021 on spatial navigation of 24-month-old rats.- Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors.- Antioxidant systemic effect of short-term Cerebrolysin® administration.- Can Cerebrolysin® influence chronic deterioration of spatial learning and memory?.- Cerebrolysin® protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia.- Further evidence that Cerebrolysin® protects cortical neurons from neurodegeneration in vitro.- Influence of BDNF and FCS on viability and programmed cell death (PCD) of developing cortical chicken neurons in vitro.- Dose-dependent effects of Cerebrolysin® on EEG and short term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia.